LEO Pharma strengthens global leadership team
The company has set out on an ambitious growth journey to become a leading provider of innovative medicines helping patients with skin diseases. To align with its strategic objectives, it re-organizes its executive leadership team.
Dr. Monica Shaw, M.D., will assume the position of Executive Vice President, Region Europe+, effective July 1, 2020. Shaw joins LEO Pharma from GSK/ViiV Healthcare in Singapore, where she was VP Commercial, Head Asia Pacific region. She is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams and an extensive specialty experience within the pharmaceutical industry including in dermatology, immuno-inflammation and rare diseases. She has held several leadership positions internationally in Europe, Asia and Latin America.
“Monica Shaw’s experience in biologics, dermatology and specialty pharma will help us to be successful in our move to launch innovative treatments and become a global leader in medical dermatology. Her combination of global experience, great leadership skills and clinical background will contribute significantly to reach our ambitions,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Nathalie Joannes will join LEO Pharma as Executive Vice President, Legal and Compliance and General Counsel from September 1, 2020. She joins LEO Pharma from Roquette Freres’ headquarters in Paris, where she has been Group General Counsel. During Joannes’ long-standing career as general counsel in the life-sciences and pharmaceutical industries, she successfully built international teams in legal, risk management and compliance in publicly traded and privately owned, global companies. She holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar.
“Nathalie Joannes has a proven track record in counseling global companies and her global pharma and life-science industry experience will be of great value for LEO Pharma on its way to become a leading provider of innovative medicines. She is a highly experienced lawyer and builder of strong international teams, which will help us immensely,” said Mazzacco.
Effective July 1, 2020, Guillaume Clemént, currently Executive Vice President, Region Europe+, will assume responsibility for Region International and the thrombosis business, after having successfully led Region Europe+ in the last four years.
Official bios
Monica Shaw
Dr. Monica Shaw, M.D., is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams to deliver business performance and successful drug development. Monica Shaw has extensive specialty experience within the pharma industry working within dermatology, immuno-inflammation, HIV, neurology and oncology. She has held several leadership positions in the global pharma industry located in i.e. Europe, Asia and Latin America.
Monica Shaw earned an M.D. M.A. and is a Member of the Royal College of Physicians.
Employment History
VP Commercial Head Asia Pacific region, GSK/ViiV Healthcare
2018 to current
General Manager, GlaxoSmithKline
2016 – 2018
VP Global Franchise Medical Head for Specialty, GlaxoSmithKline
2014 – 2016
UK Chief Scientific Officer, Novartis
2013 – 2014
Global Therapy Area Director for Clinical Development and Business Development, Norgine
2011 – 2013
Global Clinical Director ADHD, Shire
2009 – 2011
Nathalie Joannes
Nathalie Joannes holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar since 1987. During her long-standing career as general counsel in the chemical and pharmaceutical industries, she successfully built international teams and guided listed pharma companies through the legal aspects of mergers & acquisitions, partnerships, high-risk litigations, anti-trust investigations, corporate governance and compliance.
Employment History
Group General Counsel, Roquette Frères
2016 to current
EVP and Group General Counsel, IPSEN
2011 – 2015
SVP and Chief European Counsel, Genzyme
2008 – 2011
General Counsel International, Cardinal Health
2007 – 2008
Group General Counsel, Serono International
2001 – 2007
Contacts
Henrik Kyndlev
+45 3140 6180
HDTDK@LEO-Pharma.com
Images
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.
LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse
Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis19.9.2025 16:00:00 CEST | Pressemeddelelse
Late-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.
LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)18.9.2025 15:45:00 CEST | Pressemeddelelse
The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom